dc.contributor
[Escolà-Vergé L, Pigrau C, Almirante B] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain.
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Escola Verge, Laura
dc.contributor.author
Pigrau Serrallach, Carles
dc.contributor.author
Almirante Gragera, Benito
dc.date.accessioned
2025-10-24T10:20:40Z
dc.date.available
2025-10-24T10:20:40Z
dc.date.issued
2020-01-22T11:28:13Z
dc.date.issued
2020-01-22T11:28:13Z
dc.date.issued
2019-07-01
dc.identifier
Escolà-Vergé L, Pigrau C, Almirante B. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy. Infect Drug Resist. 2019;12:1853–67.
dc.identifier
https://hdl.handle.net/11351/4553
dc.identifier
000474569500003
dc.identifier
10.2147/IDR.S180905
dc.identifier.uri
https://hdl.handle.net/11351/4553
dc.description.abstract
Tractament amb ceftolozane-tazobactam; Infeccions intra-abdominals; Infeccions del tracte superior urinari; Pseudomonas aeruginosa resistentent a medicaments
dc.description.abstract
Tratamiento con ceftolozane-tazobactam; Infecciones intraabdominales; Infecciones del tracto superior urinario; Pseudomonas aeruginosa resistentes a medicamentos
dc.description.abstract
Ceftolozane-tazobactam; Complicated intra-abdominal infections; Complicated urinary tract infections; Multidrug-resistant pseudomonas aeruginosa
dc.description.abstract
The current prevalence of infections caused by multidrug-resistant (MDR) organisms is a global threat, and thus, the development of new antimicrobial agents with activity against these pathogens is a healthcare priority. Ceftolozane–tazobactam (C/T) is a new combination of a cephalosporin with a β-lactamase inhibitor that shows excellent in vitro activity against a broad spectrum of Enterobacteriaceae and Pseudomonas aeruginosa, including extended spectrum β-lactamase-producing (ESBL) strains and MDR or extensively drug-resistant (XDR) P. aeruginosa. In phase III randomized clinical trials, C/T demonstrated similar efficacy to meropenem for the treatment of complicated intra-abdominal infections (cIAIs) and superior efficacy to levofloxacin for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. The drug is generally safe and well tolerated and its PK/PD profile is very favorable. Observational studies with C/T have revealed good efficacy for the treatment of different types of infection caused by MDR or XDR P. aeruginosa, including some that originated from the digestive or urinary tracts. The place of C/T in therapy is not well defined, but its use could be recommended in a carbapenem-sparing approach for the treatment of infections caused by ESBL-producing strains or for the treatment of infections caused by P. aeruginosa if there are no other more favorable therapeutic options. Further clinical experience is needed to position this new antimicrobial drug for the empirical treatment of cIAIs or cUTIs.
dc.description.abstract
The authors are funded by the Plan Nacional de I+D+I 2013-2016 and the Instituto de Salud Carlos III, Spain [REIPI RD16/0016/0003]
dc.format
application/pdf
dc.relation
Infection and Drug Resistance;12
dc.relation
https://www.dovepress.com/infection-and-drug-resistance-journal
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Resistència als medicaments
dc.subject
Aparell urinari - Infeccions
dc.subject
Intraabdominal - Infeccions
dc.subject
DISEASES::Bacterial Infections and Mycoses::Infection::Intraabdominal Infections
dc.subject
DISEASES::Bacterial Infections and Mycoses::Infection::Urinary Tract Infections
dc.subject
PHENOMENA AND PROCESSES::Microbiological Phenomena::Drug Resistance, Microbial
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos
dc.subject
ENFERMEDADES::infecciones bacterianas y micosis::infección::infecciones urinarias
dc.subject
ENFERMEDADES::infecciones bacterianas y micosis::infección::infecciones intraabdominales
dc.title
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
